Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
Aymeric Couturier, Nephrologist at the American Hospital, Member of the Clinical Research Committee of SFNDT – Francophone Society of Nephrology, Dialysis, and Transplantation shared on LinkedIn:
”Anticoagulation and Advanced CKD: Negative Results from the TRACK Study Published in JAMA
In 1,458 patients with stage 4–5 CKD or on dialysis, low-dose rivaroxaban (2.5 mg twice daily) did not reduce major cardiovascular events compared with placebo after a median follow-up of 1.7 years:
Primary endpoint:
HR 1.09 (95% CI 0.87–1.36; p=0.46)
Cardiovascular events:
22.6% vs 20.7%
Major bleeding:
- significant increase with rivaroxaban
- HR 1.51 (95% CI 1.02–2.22; p=0.04)
The trial was terminated early due to futility and suspicion of ‘net harm.’
These results contrast with those of COMPASS and VOYAGER-PAD, likely due to:
- the pro-inflammatory and pro-thrombotic profile of patients with advanced CKD,
- the lack of combination with aspirin,
- a high rate of treatment discontinuation (~28%).
- 42.1% of all deaths were sudden cardiac deaths.
Important clinical message:
Antithrombotic strategies validated in the general cardiovascular population cannot be directly extrapolated to patients with advanced kidney disease or on dialysis.
These results also raise the question of anticoagulation in atrial fibrillation among dialysis patients, an area where randomized clinical trials remain limited.”
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community